Home » Authors » Mark McCarty

Articles by Mark McCarty

Trials difficult, but needed, for CAD validity vs. human reader

March 13, 2008

By Mark McCarty

MedPAC on Medicare: Medicare FFS plans reported as costlier than oft-criticized MA

March 13, 2008

By Mark McCarty

FDA Amendment’s effects will take time to impact industry

March 12, 2008

By Mark McCarty

Boosters of personalized medicine wary of hyperbole, public backlash

March 11, 2008

By Mark McCarty

Stand-alone and reader tests required for PMAs for CAD

March 7, 2008

By Mark McCarty

FDA & industry say current regulations enough for nano

March 6, 2008

By Mark McCarty

IOM panel: colorectal cancer testing lags despite coverage

March 6, 2008

By Mark McCarty

Trials difficult, but needed, for CAD validity vs. human reader

March 6, 2008

By Mark McCarty

Washington roundup: Medicare fraud effort blasted as federal program ‘run amok’

March 4, 2008

By Mark McCarty

FDA chief says much needed to meet ‘jet stream’ of change

March 4, 2008

By Mark McCarty

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...